136 related articles for article (PubMed ID: 38417222)
21. KRAS and BRAF mutations in prostate carcinomas of Chinese patients.
Shen Y; Lu Y; Yin X; Zhu G; Zhu J
Cancer Genet Cytogenet; 2010 Apr; 198(1):35-9. PubMed ID: 20303012
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
[TBL] [Abstract][Full Text] [Related]
23. Intraductal Carcinoma of the Prostate without High-Grade Invasive Adenocarcinoma: Report of Two Cases and Review of the Literature.
Ortiz-Rey JA; Bellas-Pereira A; San Miguel-Fraile P; Morellón-Baquera R; Domínguez-Arístegui P; González-Carreró Fojón J
Arch Esp Urol; 2022 Nov; 75(9):738-745. PubMed ID: 36472055
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C; Hassel JC
Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5.
Chen X; Yang Y; Wang W; Han B; Qi M; Geng S; Xu J; Zhang Q; Wang X; Chen S; Shi K; Ke X; Zhang J
Pathol Res Pract; 2020 Jan; 216(1):152693. PubMed ID: 31734052
[TBL] [Abstract][Full Text] [Related]
26. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
27. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives.
Zong Y; Montironi R; Massari F; Jiang Z; Lopez-Beltran A; Wheeler TM; Scarpelli M; Santoni M; Cimadamore A; Cheng L
Eur Urol Focus; 2021 Sep; 7(5):955-963. PubMed ID: 33132109
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy.
Aizawa R; Tsuzuki T; Haga H; Nakamura K; Ogata T; Inoue T; Kobayashi T; Akamatsu S; Goto T; Ogawa O; Mizowaki T
Cancer Sci; 2022 Jul; 113(7):2425-2433. PubMed ID: 35514196
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
30. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.
Dawkins HJ; Sellner LN; Turbett GR; Thompson CA; Redmond SL; McNeal JE; Cohen RJ
Prostate; 2000 Sep; 44(4):265-70. PubMed ID: 10951489
[TBL] [Abstract][Full Text] [Related]
31. Intraductal carcinoma of the prostate: What we know and what we do not know.
Chen X; Ding B; Zhang P; Geng S; Xu J; Han B
Pathol Res Pract; 2018 May; 214(5):612-618. PubMed ID: 29628124
[TBL] [Abstract][Full Text] [Related]
32. BRAF and KRAS mutations in prostatic adenocarcinoma.
Cho NY; Choi M; Kim BH; Cho YM; Moon KC; Kang GH
Int J Cancer; 2006 Oct; 119(8):1858-62. PubMed ID: 16721785
[TBL] [Abstract][Full Text] [Related]
33. Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
[TBL] [Abstract][Full Text] [Related]
34. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
[TBL] [Abstract][Full Text] [Related]
36. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
38. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
[TBL] [Abstract][Full Text] [Related]
39. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
40. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
